ClinTec International Expands Capabilities in Spain
News May 24, 2016
ClinTec International has continued to deliver strong growth and further international expansion with the opening of two new offices in Spain, alongside the appointment of Carlos Palacios as the company’s new Regional Manager for Spain and Portugal. ClinTec International is an award winning, full-service, global Contract Research Organisation and Functional Service Provider. Headquartered in the United Kingdom, ClinTec provides innovative solutions consisting of customised clinical research solutions to progress drug development in a fast, flexible and focused way.
ClinTec is working globally to deliver ground-breaking clinical research in challenging areas such as immuno-oncology and rare diseases. ClinTec is adding significant depth of capability to Spain and Portugal as a key target market in Europe, moving to a larger office in Barcelona, opening a new office in Madrid and strengthening the management team with the appointment of Carlos Palacios as Regional Manager. Carlos joins ClinTec from Merck Serono where he had oversight of Global Trials across Spain, Portugal, Israel and the Netherlands.
He has over 16 years of experience in the clinical research industry at local and global levels. Carlos has degrees in both Pharmaceuticals and Veterinary Science, along with an MBA from Comillas Pontifical University, ICAI - ICADE in Madrid. In addition, Carlos supports the development of Clinical Research Education by lecturing at several universities across Spain.
The creation of the new Regional Management post is in line with the significant increase in the size of ClinTec’s Spanish based team which has grown considerably over the course of the last 12 months. The opening of larger premises in Barcelona and a new hub in Madrid cement the capability for expanding the local clinical trial portfolio, whilst accommodating larger functional outsourcing engagements in Spain.
The CEO and founder of ClinTec International, Dr Rabinder Buttar said, “We have now entered a new phase of development and are on track to scale the organisation considerably in the next 12 months as we enter our 20th year of growth. The creation of the new Regional Management post and the opening of the two new offices in Madrid and Barcelona signal that ClinTec is developing and expanding in line with our current clients’ needs and that as a company we are ready to take on new business of all sizes. I am delighted Carlos has joined our team at ClinTec, as we continue to expand our business in the Spanish and Portugese region.”
Bobby Bal, Chief Commercial Officer and Executive Vice President, commented: “ClinTec has a strong heritage in Europe and we are executing on our plan to provide even greater depth of capability within the key European markets. Our recent expansion in Spain highlights our on-going commitment to address the growing needs of our loyal client base, including the delivery of complex class-leading oncology programmes. It is an exciting time at ClinTec as we seek to keep innovating and investing within our solutions and capabilities.”
In addition to vast expertise in oncology and rare diseases, ClinTec has successfully conducted many trials in other therapeutic areas including anti-infectives, cardiology, dermatology, gastroenterology, neurology, respiratory medicine and rheumatology. ClinTec is also well-positioned to conduct studies for investigational drugs, biologicals, medical devices and orphan drugs. The Executive Leadership Team drive the continued entrepreneurial growth of the organisation and new innovative offerings by enabling flexible, bespoke solutions to meet clients’ needs, whilst at the same time creating an excellent working environment that supports and nurtures staff.
Synthetic biologists look to re-engineer cells to make complex molecules for specific needs, including pharmaceuticals. But the trial-and-error process is difficult and time-consuming. Now, by combining two state-of-the-art research approaches, researchers have created a fast, efficient way to engineer and analyze metabolic pathways.READ MORE